Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLAY: Revaccination with Prevenar 13
NCT00853749Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- Dec 2009
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in invasive pneumococcal disease (IPD), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Serotype-specific IgG Antibody Concentration >= 0.35 mcg/mL at 1 month and Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers >= 1:8 at 1 month. Started May 2009; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on NCT00853749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00853749.